Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22690991 | 1.00 | MAPT (0.61) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL13154843 | 0.93 | KDM4E (0.65) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL13154827 | 0.89 | MAPT (0.46) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL5996852 | 0.86 | MAPT (0.44) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL5996088 | 0.86 | ALDH1A1 (0.44) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL13670442 | 0.85 | MAPT (0.65) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13954541 | 0.84 | RORC (0.46) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL5997173 | 0.82 | MAPT (0.61) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL4703109 | 0.81 | KDM4E (0.56) | MAPTKDM4EALDH1A1LMNARORC | |
| SCHEMBL5996876 | 0.79 | RORC (0.48) | MAPTKDM4EALDH1A1LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220273669-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP DOHME CORP. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-7608643-B2 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608643-B2 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060281778-A1 | Compounds for inhibiting KSP Kinesin activity | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281778-A1 | Compounds for inhibiting KSP Kinesin activity | KIFC1, KIF5B, KIF2C | MAPT 434/4885KDM4E 501/4885ALDH1A1 2371/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | MAPT 1628/4885KDM4E 1345/4885ALDH1A1 2905/4885 |
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | NPR1, NPPA, NPR3 | MAPT 4803/4885KDM4E 3367/4885ALDH1A1 2115/4885 |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | MAPT 434/4885KDM4E 501/4885ALDH1A1 2371/4885 |
| US-20220273669-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | NPR1, NPPA, NPR3 | MAPT 4796/4885KDM4E 3469/4885ALDH1A1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.